Mitchell S.V. Elkind, MD, MS, MPhil

Academic Appointments

  • Professor of Neurology and Epidemiology (in the Gertrude H. Sergievsky Center)

Mitchell Elkind, MD, MS is a tenured Professor of Neurology and Epidemiology at Columbia University Irving Medical Center, and Chief of the Division of Neurology Clinical Outcomes Research and Population Sciences (Neuro CORPS) in the Neurology Department.

Dr. Elkind received his medical degree from Harvard Medical School, and trained in Internal Medicine at Brigham and Women’s Hospital and in Neurology at Massachusetts General Hospital, both in Boston, MA. He completed a fellowship in Vascular Neurology and Neuroepidemiology at Columbia University Medical Center under the mentorship of Dr. Ralph Sacco. Dr. Elkind holds a Master’s degree in Epidemiology from Columbia’s Mailman School of Public Health.

Dr Elkind’s research focuses on stroke prevention, inflammatory and infectious biomarkers in stroke risk prediction, atrial cardiopathy, immune therapy for acute stroke, and vascular causes of cognitive aging. Dr. Elkind is the Principal Investigator of several independent investigator awards from NIH/NINDS, including the ARCADIA trial of apixaban vs aspirin for atrial cardiopathy in cryptogenic stroke; the Northern Manhattan Study (NOMAS), an epidemiological study of stroke risk factors; the Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART), a clinical trial evaluating short-term high-dose statin therapy in acute stroke; and the Levels of Inflammatory Markers in Treatment of Stroke (LIMITS) study.

Dr. Elkind also has a longstanding commitment to medical education and research training. In addition to leading the Columbia Neurology residency and fellowship programs, he serves as editor of the AHA/ASA Stroke journal’s new International Stroke Early Career and Training Section (InterSECT). He runs two NIH-funded research training programs for residents and fellows. Dr. Elkind has served on several AHA/ASA committees, including 3 terms on the National Board of Directors (2014-2020), 2 terms as Chair of the ASA Advisory Committee (2016-2020), and co-chair or member of several writing committees for guidelines and scientific statements. He co-chaired the writing committee for the 2012 scientific statement on the inclusion of stroke as an outcome and risk equivalent in vascular disease risk scores, and currently serves as Chair of the stroke section of the annual statistical update. Dr. Elkind will become President of the American Heart Association July 1, 2020.

Dr. Elkind lives in New York City with his wife (novelist and children’s book author Rachel Vail) 2 sons (Zachary and Liam), and a pet tortoise (Lightning).

Research focuses on different inflammatory markers and infections, such as C. pneumoniae and periodontal disease, as potential causes of atherosclerosis and ischemic stroke; se of high-resolution duplex doppler ultrasonography as a measure of stroke risk; amd clinical trials of neuroprotectants and surgical hemicraniectomy for acute stroke, and antiplatelet and of other therapies for stroke prevention.

Departmental Appointments

  • Department of Neurology
    Division of Stroke and Cerebrovascular Disease
  • Department of Epidemiology

Education and Training

  • Harvard Medical School
  • Internship: Brigham & Women's Hospital - Harvard
  • Residency: Massachusetts General Hospital
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center

Centers / Institutes / Programs

  • Gertrude H. Sergievsky Center

Research Interests

  • Relationship between infection, inflammation and stroke

NIH Grants

  • DECISION FOR UNDERSTANDING IMMUNE MEDIATED MECHANISMS UNDERLYING POST-STROKE COGNITIVE DECLINE (Private)

    Jan 1 2020 - Dec 31 2024

    NEUROEPIDEMIOLOGY TRAINING PROGRAM (Federal Gov)

    Jul 1 2019 - Jun 30 2024

    TESTING A RAPID OUTPATIENT MANAGEMENT STRATEGY ON PTSD, CARDIOVASCULAR AND REHOSPITALIZATION RISK IN TIA AND MINOR STROKE SURVIVORS EVALUATED IN THE EMERGENCY DEPARTMENT (Federal Gov)

    Aug 1 2018 - Jun 30 2023

    ATRIAL CARDIOPATHY AND ANTITHROMBOTIC DRUGS IN PREVENTION AFTER CRYPTOGENIC STROKE (ARCADIA) (Federal Gov)

    May 1 2017 - Apr 30 2023

    POOR SLEEP, SEDENTARY BEHAVIOR, AND SECONDARY CARDIOVASCULAR RISK IN STROKE AND TIA PATIENTS (Federal Gov)

    May 4 2018 - Mar 31 2023

    SERVICE AGREEMENT - RELATED TO COST EFFECTIVENESS MODEL (P&S Industry Clinical Trial)

    Jan 18 2018 - Jan 18 2023

    ATRIAL CARDIOPATHRY AND ANTITHROMBOTIC DRUGS IN PREVENTION AFTER CRY[TOGENIC STROKE(ARCADIA)/RD 003152 (P&S Industry Clinical Trial)

    Aug 2 2017 - Aug 2 2022

    REVEAL AF 2017 SERVICE AGREEMENT (P&S Industry Clinical Trial)

    Jul 20 2017 - Jul 20 2022

    THE EFFECT OF LOWER PRESSURE OVER THE LIFE COURSE ON LATE-LIFE COGNITION IN BLACK (Federal Gov)

    Aug 1 2017 - May 31 2022

    RACIAL DISPARITIES, INFLUENZA LIKE ILLNESS AND THE ASSOCIATION BETWEEN SHORT-TERM EXPOSURE TO AMBIENT AIR POLLUTION AND CARDIOVASCULAR OUTCOMES (Federal Gov)

    Sep 24 2017 - Jun 30 2021

    CLINICAL AND TRANSLATIONAL SCIENCE AWARD (Federal Gov)

    Jul 1 2016 - May 31 2021

    IMPACT OF PTSD ON CARDIOVASCULAR RISK IN SURVIVORS OF STROKE AND TRANSIENT ISCHEMIC ATTACK (Federal Gov)

    Jun 20 2016 - Mar 31 2021

    PREVALENCE AND PREDICTORS OF ASYMPTOMATIC ATRIAL FIBRILLATION IN THE COMMUNITY (Federal Gov)

    Apr 1 2014 - Jul 31 2020

    COLUMBIA GENIE (GENOMIC INTEGRATION WITH EHR) (Federal Gov)

    Sep 1 2015 - Jun 30 2020

    BIOGEN IDEC SCIENTIFIC LEADER ACTIVITIES ON PROTOCOL 101SK201. A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF IV NATALIZUMAB (BG00002) (P&S Industry Clinical Trial)

    Aug 26 2013 - Aug 26 2018

    THE TRAJECTORY OF FUNCTIONAL STATUS AND QUALITY OF LIFE BEFORE AND AFTER STROKE (Federal Gov)

    Apr 1 2013 - Mar 31 2018

    TRIAGE AND OUTPATIENT EVALUATION OF PATIENTS WITH TIA AND MINOR STROKE THE RAPID ACCESS VASCULAR EVALUATION-NEUROLOGY (RAVEN) APPROACH (NY State Gov)

    Dec 31 2015 - Dec 30 2017

    NEW YORK COLUMBIA COLLABORATIVE SPOTRIAS (Federal Gov)

    Aug 1 2010 - Jul 31 2016

    COMPARATIVE EFFECTIVENESS ANALYSIS OF TREAT-TO-TARGET AND RISK-BASED BLOOD PRESSURE CONTROL GUIDELINES (Federal Gov)

    Aug 19 2011 - Jun 30 2016

    PHYSICAL ACTIVITY PATTERNS VIA NEW DIMENSION-INFORMATIVE CLUSTER MODELS (CHEUNG/ELKIND) (Federal Gov)

    Aug 17 2012 - Apr 30 2016

    FGF-23 AND PHOSPHORUS IN STROKE, SUBCLINICAL VASCULAR DAMAGE, AND COGNITION (Federal Gov)

    Mar 16 2012 - Feb 28 2016

    STROKE INCIDENCE AND RISK FACTORS IN A TRI-ETHNIC REGION (Federal Gov)

    Sep 30 2015 - Dec 31 2015

    MINORITIES WITH ICH (Federal Gov)

    Jul 1 2010 - Jul 31 2015

    MINORITIES WITH ICH (Federal Gov)

    Jul 1 2010 - Jun 30 2015

    STROKE INCIDENCE AND RISK FACTORS IN A TRI-ETHNIC REGION (Federal Gov)

    Apr 1 2008 - Mar 31 2015

    MECHANISMS OF EARLY RECURRENCE IN INTRACRANIAL ATHEROSCLEROTIC DISEASE (Federal Gov)

    Mar 1 2014 - Feb 28 2015

    VASCULAR EFFECTS OF INFECTION IN PEDIATRIC STROKE (Federal Gov)

    Aug 5 2009 - Jul 31 2014

    MODIFIABLE RISK FACTORS IN STROKE INCIDENCE AND MORTALITY AMONG WOMEN (Federal Gov)

    Jul 1 2011 - Jun 30 2014

    THE VERTEBROBASILAR FLOW EVALUATION AND RISK OF TRANSIENT ISCHEMIC ATTACK & STROKE (VERITAS) STUDY (Federal Gov)

    Jul 1 2009 - Jun 30 2014

    VASCULAR EFFECTS OF INFECTION IN PEDIATRIC STROKE (Federal Gov)

    Aug 5 2009 - Jul 31 2013

    DOSE AND TREATMENT SELECTION IN CLINICAL TRIALS (Federal Gov)

    Jul 8 2006 - Jun 30 2013

    THE ROLE OF COPETIN, MIDREGIONAL NATRIURETIC PEPTIDE AND PROCALCITONIN AS MARKERS OF ISCHEMIC STROKE RISK IN THE NORTHERN MANHATTAN STUDY (Private)

    Jan 1 2012 - May 31 2013

    STENTING VS AGGRESSIVE MEDICAL MANAGEMENT FOR PREVENTING RECURRENT EVENTS IN INTRACRANIAL STENOSIS (SAMMPRIS) (Federal Gov)

    May 1 2008 - Apr 30 2013

    STROKE INCIDENCE AND RISK FACTORS IN A TRI-ETHNIC REGION (Federal Gov)

    Apr 1 2008 - Mar 31 2013

    USE OF A MENTORED PEER REVIEW PROGRAM TO ENHANCE NEUROLOGY R ESIDENT EDUCATION ON THE BASIC CONCEPTS OF BIOSTATISTICS, RE (Private)

    Jan 1 2012 - Dec 31 2012

    LEVELS OF INFLAMMATORY MARKERS IN THE TREATMENT OF STROKE (LIMITS) (P&S Industry Clinical Trial)

    May 18 2004 - Aug 17 2012

    SECONDARY PREVENTION OF SMALL SUBCORTICAL STOKES (Federal Gov)

    Dec 1 2009 - Jul 31 2012

    VASCULAR EFFECTS OF INFECTION IN PEDIATRIC STROKE (Federal Gov)

    Aug 5 2009 - Jul 31 2012

    VIPS: VASCULAR EFFECTS OF INFECTION IN PEDIATRICS STROKE (Federal Gov)

    Aug 5 2009 - Jul 31 2012

    LP-PLA2 AND RISK OF STROKE IN A PROSPECTIVE COHORT STUDY IN A MULTI-ETHNIC POPULATION (Private)

    Jan 13 2010 - Jan 12 2012

    SECONDARY PREVENTION OF SMALL SUB-CORTICAL STROKES - (SPS3) (Federal Gov)

    Feb 8 2008 - Jun 30 2011

    NMT MEDICAL--G980031 (P&S Industry Clinical Trial)

    Aug 9 2007 - Jun 30 2011

    LEVELS OF INFLAMMATORY MARKERS IN TREATMENT OF STROKE (Federal Gov)

    May 25 2005 - Apr 30 2011

    INFLAMMATORY AND INFECTIOUS BURDEN AND RISK OF STROKE (Federal Gov)

    Mar 1 2004 - Feb 28 2011

    INFLAMMATION, LEUKOCYTE ACTIVATION, AND STROKE RISK (Private)

    Jul 1 2003 - Jun 30 2007

    ORAL INFECTIONS, CAROTID ATHEROSCLEROSIS AND STROKE (Federal Gov)

    Jun 15 2000 - Mar 24 2006